ES2601892T3 - Pentapolímero aleatorio para el tratamiento de enfermedades autoinmunes - Google Patents

Pentapolímero aleatorio para el tratamiento de enfermedades autoinmunes Download PDF

Info

Publication number
ES2601892T3
ES2601892T3 ES12774372.2T ES12774372T ES2601892T3 ES 2601892 T3 ES2601892 T3 ES 2601892T3 ES 12774372 T ES12774372 T ES 12774372T ES 2601892 T3 ES2601892 T3 ES 2601892T3
Authority
ES
Spain
Prior art keywords
pentapolymer
treatment
random
autoimmune diseases
vehicle
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES12774372.2T
Other languages
English (en)
Inventor
Ehud Marom
Shai Rubnov
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mapi Pharma Ltd
Original Assignee
Mapi Pharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mapi Pharma Ltd filed Critical Mapi Pharma Ltd
Application granted granted Critical
Publication of ES2601892T3 publication Critical patent/ES2601892T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G69/00—Macromolecular compounds obtained by reactions forming a carboxylic amide link in the main chain of the macromolecule
    • C08G69/02—Polyamides derived from amino-carboxylic acids or from polyamines and polycarboxylic acids
    • C08G69/08—Polyamides derived from amino-carboxylic acids or from polyamines and polycarboxylic acids derived from amino-carboxylic acids
    • C08G69/10—Alpha-amino-carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/785—Polymers containing nitrogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Polymers & Plastics (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Un pentapolímero o una sal del mismo, que es un copolímero lineal de alanina, ácido glutámico, lisina, tirosina y fenilalanina.

Description

imagen1
imagen2
imagen3
imagen4
imagen5
imagen6
imagen7
imagen8
imagen9
suspensión blanca homogénea, capaz de ser extraída e inyectada a través de una aguja adecuada.
Formación de vehículos:
5 Vehículo 1: solución salina, 0,9% de NaCL en agua estéril Vehículo 2: agua para inyección (WFI)
Reactivos:
MOG 35-55: (GL BiochemCo. Ltd; Shanghái, P.R. China). MOG 35-55. El MOG 35-55 se disuelve en solución salina a una concentración de 2 mg/ml.
Adyuvante Completo de Freund (CFA) (Cat: F5881; Sigma-Aldrich; St. Louis, MO, USA).Se añade la cepa Mycobacterium tuberculosis H37RA matada por calor (Cat: 231141; Difco; Detroit, MI, USA) al adyuvante completo 15 de Freund a una concentración final de 4 mg/ml.
Toxina de Bordetella pertussis (PTX): (Cat: P7208; Sigma-Aldrich; St. Louis, MO, USA).
Usando un homogeneizador de alta velocidad, la solución MOG anterior se emulsifica con volumen igual del CFA modificado en hielo para 30.000 rpm durante 1,5 horas.
Animales:
Ratones C57BL/6, hembra, 7 -9 semanas, 17 -20 g.
25 Adaptación: no menos de 7 días. Ambiente: ambiente Libre de Patógenos Específicos (SPF) Temperatura ambiente: 20 -26C Humedad relativa ambiente: 40 -70% Ciclo de luz: luz fluorescente durante 12 horas de luz (08:00 -20:00) y 12 horas de oscuridad. Alojamiento de animales: 3-4 ratones/caja por grupo de tratamiento Alimentación: acceso libre a comida (irradiada, Shanghai SLAC Laboratory Animal Co. Ltd., China). Agua: acceso libre a agua (agua del grifo filtrada por Mol Ultrapure Water System).
Asignación a grupos de tratamiento: 35 Los animales se asignaron a los grupos de tratamiento por aleatorización en software Biobook para lograr peso medio de grupo similar, que proporciona control del error sistemático.
Tabla 1 -Grupo y régimen de dosificación
45
55
Grupo Artículo de Prueba N Vía Conc. Dosificción Régimen Dosis en (días)
mg/ml ml/ratones mg/ratone s
1 PPb 10 s.c. 10 0.2 2 q.d. DO-9
2 GAb 10 i.m. 25 0.2 5 q.d. D0, 1, 14, 15, 28,29
3 GAb 10 i.m. 25 0.2 5 q.d. D0, 14, 28
4 GAb 10 i.m. 25 0.2 5 q.d. D0, 7, 14,21, 28
5 GA-depósitob 10 i.m. 312 0.2 62.5* q.d. D0, 1, 14, 15, 28,29
6 GA-depósitob 10 i.m. 312 0.2 62.5* q.d. D0, 14, 28
7 GA-depósitob 10 i.m. 312 0.2 62.5* q.d. D0, 7, 14,21, 28
8 GAb 10 s.c. 10 0.2 2 q.d. DO-9
9 Veha 10 s.c. N/A 0.2 N / q.d. DO-9
a: Vehículo en solución salina b: Vehículo es WFI * contenido de Ga es 80 mg/g de producto formulado "GA-depósito", es decir 5 mg/ratones/día de GA.
11
imagen10

Claims (1)

  1. imagen1
ES12774372.2T 2011-04-21 2012-04-16 Pentapolímero aleatorio para el tratamiento de enfermedades autoinmunes Active ES2601892T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161477610P 2011-04-21 2011-04-21
US201161477610P 2011-04-21
PCT/IL2012/050138 WO2012143924A1 (en) 2011-04-21 2012-04-16 Random pentapolymer for treatment of autoimmune diseases

Publications (1)

Publication Number Publication Date
ES2601892T3 true ES2601892T3 (es) 2017-02-16

Family

ID=47041117

Family Applications (1)

Application Number Title Priority Date Filing Date
ES12774372.2T Active ES2601892T3 (es) 2011-04-21 2012-04-16 Pentapolímero aleatorio para el tratamiento de enfermedades autoinmunes

Country Status (4)

Country Link
US (1) US9200114B2 (es)
EP (1) EP2699317B1 (es)
ES (1) ES2601892T3 (es)
WO (1) WO2012143924A1 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE49251E1 (en) 2010-01-04 2022-10-18 Mapi Pharma Ltd. Depot systems comprising glatiramer or pharmacologically acceptable salt thereof
US20160128951A1 (en) * 2013-07-29 2016-05-12 Aizant Drug Research Solutions Pvt Ltd Pharmaceutical compositions of fingolimod
JP2018536484A (ja) 2015-11-25 2018-12-13 インセプト・リミテッド・ライアビリティ・カンパニーＩｎｃｅｐｔ，Ｌｌｃ 形状変化する薬物送達デバイス及び方法
US20210220428A1 (en) * 2016-06-30 2021-07-22 Stem Cell Medicine Ltd. Treatment of inflammatory bowel disease with long acting glatiramer and adipose-derived stem cells
WO2018042423A1 (en) 2016-08-28 2018-03-08 Mapi Pharma Ltd. Process for preparing microparticles containing glatiramer acetate
US12097292B2 (en) 2016-08-28 2024-09-24 Mapi Pharma Ltd. Process for preparing microparticles containing glatiramer acetate
CN110382052A (zh) 2017-03-26 2019-10-25 Mapi医药公司 用于治疗进展型形式的多发性硬化症的格拉替雷储库系统
CN110709091A (zh) 2017-05-15 2020-01-17 干细胞医药有限公司 使用长效格拉替雷和脂肪源性干细胞治疗多发性硬化症
US11510946B2 (en) 2017-05-15 2022-11-29 Stem Cell Medicine Ltd. Treatment of multiple sclerosis with adipose-derived stem cells

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3536809A (en) 1969-02-17 1970-10-27 Alza Corp Medication method
US3598123A (en) 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
IL36670A (en) * 1971-04-21 1974-09-10 Sela M Therapeutic basic copolymers of amino acids
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US4008719A (en) 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
IE58110B1 (en) 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
US5073543A (en) 1988-07-21 1991-12-17 G. D. Searle & Co. Controlled release formulations of trophic factors in ganglioside-lipsome vehicle
IT1229203B (it) 1989-03-22 1991-07-25 Bioresearch Spa Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative.
US5120548A (en) 1989-11-07 1992-06-09 Merck & Co., Inc. Swelling modulated polymeric drug delivery device
US5580578A (en) 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
US5578442A (en) 1992-03-23 1996-11-26 Vivorx, Inc. Graft copolymers of polycationic species and water-soluble polymers, and use therefor
US5591767A (en) 1993-01-25 1997-01-07 Pharmetrix Corporation Liquid reservoir transdermal patch for the administration of ketorolac
US5800808A (en) 1994-05-24 1998-09-01 Veda Research And Development Co., Ltd. Copolymer-1 improvements in compositions of copolymers
IT1270594B (it) 1994-07-07 1997-05-07 Recordati Chem Pharm Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida
US5858964A (en) 1995-04-14 1999-01-12 Yeda Research And Development Co. Ltd. Pharmaceutical compositions comprising synthetic peptide copolymer for prevention of GVHD
IT1276690B1 (it) 1995-06-09 1997-11-03 Ira Srl Sistema di inclusione a rilascio controllato di acido glicolico in beta-ciclodestrine e procedimento di preparazione di detto sistema
US6214791B1 (en) 1997-01-10 2001-04-10 Yeda Research And Development Co. Ltd. Treatment of multiple sclerosis through ingestion or inhalation of copolymer-1
ES2527760T3 (es) * 1998-07-23 2015-01-29 Yeda Research And Development Co., Ltd. Tratamiento de enfermedad de Crohn con copolímero 1 y polipéptidos
IL141021A0 (en) 1998-07-23 2002-02-10 Yeda Res & Dev Treatment of autoimmune conditions with copolymer 1 and related copolymers
US6514938B1 (en) * 1998-09-25 2003-02-04 Yeda Research And Development Co. Ltd. At The Weizmann Institute Of Science Copolymer 1 related polypeptides for use as molecular weight markers and for therapeutic use
EP1128839A4 (en) 1998-11-12 2002-10-09 Yeda Res & Dev PHARMACEUTICAL COMPOSITIONS CONTAINING COPOLYMERS OF SYNTHETIC PEPTIDES AND METHODS FOR PREVENTING AND TREATING GVHD AND HVGD
JP4328050B2 (ja) 2000-01-20 2009-09-09 イエダ リサーチ アンド デベロップメント カンパニー リミテッド 神経保護療法のためのコポリマー１、関連ペプチド及びポリペプチドならびにそれらによって処理されたｔ細胞の使用
ATE314860T1 (de) 2000-06-07 2006-02-15 Yeda Res & Dev Verwendung des copolymer-1 peptids sowie von damit verwandten peptiden und polypeptiden und von damit behandelten t-zellen zur neuroprotektion vor glutamattoxizitaet
US6835711B2 (en) 2001-06-28 2004-12-28 Yeda Research And Development Co. Ltd. Use of poly-Glu,Tyr for neuroprotective therapy
HUP0401079A3 (en) 2001-07-10 2008-04-28 Teva Pharma Drug delivery system for zero order, zero order-biphasic, ascending or descending drug delivery
EP2123669A1 (en) * 2001-10-03 2009-11-25 The President and Fellows of Harvard College Copolymers for suppression of autoimmune diseases, and methods of use
US7230085B2 (en) 2001-11-28 2007-06-12 Immunomedics, Inc. Anti-DOTA antibody
HU228207B1 (hu) 2001-12-06 2013-01-28 Yeda Res & Dev Vakcina és eljárás mozgatóneuron-betegségek kezelésére
US8871241B2 (en) 2002-05-07 2014-10-28 Psivida Us, Inc. Injectable sustained release delivery devices
CA2512735C (en) 2003-01-07 2016-03-08 Yeda Research And Development Co. Ltd. Eye-drop vaccine containing copolymer 1 for therapeutic immunization
PT1592384E (pt) 2003-01-21 2013-01-28 Yeda Res & Dev Cop-1 para o tratamento de doenças inflamatórias do intestino
US20050142205A1 (en) 2003-07-18 2005-06-30 Julia Rashba-Step Methods for encapsulating small spherical particles prepared by controlled phase separation
MXPA06000720A (es) 2003-07-18 2006-08-23 Baxter Int Metodos para fabricacion, usos y composiciones de particulas esfericas pequenas preparadas por separacion de fase controlada.
JP2007500693A (ja) 2003-07-31 2007-01-18 イエダ リサーチ アンド デベロップメント カンパニー リミテッド 移植片拒絶反応を予防するための合成ペプチドコポリマーを含む併用療法
JP2007509981A (ja) 2003-10-31 2007-04-19 テバ ファーマシューティカル インダストリーズ リミティド 薬物デリバリー用ナノ粒子
EP2301569B1 (en) 2003-11-12 2018-05-02 Yeda Research and Development Co. Ltd. Vaccine and method for treatment of neurodegenerative diseases
EP2633853A1 (en) 2004-01-12 2013-09-04 The Trustees of The University of Pennsylvania Long-term delivery formulations and methods of use thereof
CA2558655A1 (en) * 2004-03-01 2005-09-15 Kai W. Wucherpfennig Methods and compositions for treatment of autoimmune diseases
US7576051B2 (en) 2004-03-11 2009-08-18 Sanyo Chemical Industries, Ltd. Wound dressing for accelerating epidermal regeneration
US7655221B2 (en) * 2004-05-07 2010-02-02 Peptimmune, Inc. Methods of treating disease with random copolymers
DE602005018800D1 (de) 2004-09-09 2010-02-25 Teva Pharma Verfahren zur herstellung von polypeptidmischungen unter anwendung von aufgereinigter bromwasserstoffsäure
WO2006057003A2 (en) 2004-11-29 2006-06-01 Yeda Research And Development Co. Ltd. Induction of neurogenesis and stem cell therapy in combination with copolymer 1
AU2006211101A1 (en) 2005-02-02 2006-08-10 Yeda Research And Development Co. Ltd. At The Weizmann Institute Of Science Synthetic peptide copolymers for treatment and prevention of cardiovascular disorders
US7517856B2 (en) 2005-10-11 2009-04-14 Ben-Gurion University Of The Negev Research And Development Authority Bioconjugates comprising sulfated polysaccharides and their uses
ES2565035T3 (es) 2006-04-28 2016-03-30 Momenta Pharmaceuticals, Inc. Métodos para evaluar mezclas de péptidos
CA2656463C (en) 2006-06-28 2015-12-01 Yeda Research And Development Co. Ltd. Method of treatment of age-related macular degeneration
WO2008075365A1 (en) 2006-12-20 2008-06-26 Yissum Research Development Company Of The Hebrew University Of Jerusalem Compositions and methods for treatment of age related degeneration of the retina
DK2187882T3 (da) 2007-07-11 2013-04-08 Medicinova Inc Behandling af progressiv neurodegenerativ sygdom med ibudilast
EP2195008A1 (en) 2007-09-24 2010-06-16 Hadasit Medical Research Services & Development Ltd. Use of copolymer 1 for treatment of muscular dystrophy
WO2009063459A2 (en) 2007-11-13 2009-05-22 Yeda Research And Development Co. Ltd Synthetic peptide copolymers for treatment of neurodevelopmental disorders
CA2732228A1 (en) 2008-07-25 2010-01-28 The Johns Hopkins University Methods and compositions for treating and preventing autoimmune diseases
EP2398499B1 (en) 2009-02-18 2017-09-06 Eyeon Particle Sciences LLC Bi-functional co-polymer use for ophthalmic and other topical and local applications
EP3536333B1 (en) 2010-01-04 2022-08-03 Mapi Pharma Limited Depot system comprising glatiramer acetate
US8377885B2 (en) 2010-01-04 2013-02-19 Mapi Pharma Ltd. Depot systems comprising glatiramer or pharmacologically acceptable salt thereof

Also Published As

Publication number Publication date
US20130156725A1 (en) 2013-06-20
WO2012143924A1 (en) 2012-10-26
EP2699317A1 (en) 2014-02-26
EP2699317A4 (en) 2014-12-03
EP2699317B1 (en) 2016-08-10
US9200114B2 (en) 2015-12-01

Similar Documents

Publication Publication Date Title
ES2601892T3 (es) Pentapolímero aleatorio para el tratamiento de enfermedades autoinmunes
Mehdizadeh Gohari et al. Pathogenicity and virulence of Clostridium perfringens
Kathayat et al. Avian pathogenic Escherichia coli (APEC): an overview of virulence and pathogenesis factors, zoonotic potential, and control strategies
Zhang et al. Enterotoxigenic Escherichia coli: intestinal pathogenesis mechanisms and colonization resistance by gut microbiota
Hwang et al. Alteration of gut microbiota by vancomycin and bacitracin improves insulin resistance via glucagon‐like peptide 1 in diet‐induced obesity
Haiko et al. The role of the bacterial flagellum in adhesion and virulence
Johnson Fueling the immune response: what’s the cost?
Appelt et al. The flagellar regulon of Legionella—A Review
Ren et al. Dietary L-glutamine supplementation increases Pasteurella multocida burden and the expression of its major virulence factors in mice
Karriker et al. Drug pharmacology, therapy, and prophylaxis
CN108478790B (zh) Bt脂肽作为用于肥胖和相关疾病的治疗剂的用途
RU2009126604A (ru) Вакцина против salmonella
Romstad et al. Comparision of a serological potency assay for furunculosis vaccines (Aeromonas salmonicida subsp. salmonicida) to intraperitoneal challenge in Atlantic salmon (Salmo salar L.)
CN102599103A (zh) 猪呼吸道疾病综合征的防控方法
Abubakar et al. An evaluation of foot–and–mouth disease outbreak in relation to vaccination in a herd of cattle and buffaloes
Venkatesan et al. Combination vaccines against diarrheal diseases
CN102584992A (zh) 大肠杆菌外膜蛋白单克隆抗体及其制备方法和应用
Avendaño-Herrera Salmon aquaculture, Piscirickettsia salmonis virulence, and one health: Dealing with harmful synergies between heavy antimicrobial use and piscine and human health comment on
Rzeznitzeck et al. The effect of Campylobacter jejuni and Campylobacter coli colonization on the gut morphology, functional integrity, and microbiota composition of female turkeys
RU2012154628A (ru) Фармацевтическая композиция ибупрофена для инъекции
Maina et al. Staphylococcal enterotoxin A has potent superantigenic and emetic activities but not diarrheagenic activity
US20110144048A1 (en) Novel Uses of Neuraminidase Inhibitors in Infectious Diseasess
Ross et al. Rise of informal slums and the next global pandemic
Kim et al. Safety and vaccine efficacy of an attenuated Vibrio vulnificus strain with deletions in major cytotoxin genes
Domínguez-Odio et al. Technology surveillance in veterinary vaccine adjuvants (2015–2022): University-industry interaction